Talal Al-Taweel

ORCID: 0000-0001-6717-9613
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Autoimmune and Inflammatory Disorders
  • Complementary and Alternative Medicine Studies
  • Diagnosis and treatment of tuberculosis
  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • Autoimmune and Inflammatory Disorders Research
  • Pain Management and Placebo Effect
  • Diverticular Disease and Complications
  • Health Systems, Economic Evaluations, Quality of Life
  • Empathy and Medical Education
  • Psoriasis: Treatment and Pathogenesis
  • Immunodeficiency and Autoimmune Disorders
  • Gastrointestinal Tumor Research and Treatment
  • Gastrointestinal disorders and treatments
  • Health and Medical Research Impacts
  • Esophageal and GI Pathology
  • Gastrointestinal motility and disorders
  • IL-33, ST2, and ILC Pathways
  • Innovations in Medical Education
  • Chronic Lymphocytic Leukemia Research
  • Biosimilars and Bioanalytical Methods
  • Diabetes and associated disorders
  • Pregnancy and Medication Impact

Wayne State University
2024

Ministry of Health
2020-2021

McGill University
2014-2020

Kuwait University
2019

Mubarak Al Kabeer Hospital
2015-2018

Montreal General Hospital
2017

McGill University Health Centre
2013-2016

KU Leuven
2014

Background: Ustekinumab is a fully human IgG1 monoclonal antibody that blocks the biologic activity of interleukin-12/23. approved for treatment plaque psoriasis and has been shown to be effective induction maintenance clinical response in anti-TNF resistant Crohn's disease (CD). The aim study was describe real-life experience with open-label use ustekinumab CD patients.

10.1016/j.crohns.2014.06.005 article EN Journal of Crohn s and Colitis 2014-07-02

This is a retrospective single-center study of 417 consecutive patients with coronavirus disease 2019 (COVID-19) admitted to Jaber Al-Ahmad Hospital in Kuwait between February 24, 2020 and May 2020. In total, 39.3% were asymptomatic, 41% symptomatic mild/moderate symptoms, 19.7% the intensive care unit (ICU). Most common symptoms cohort fever (34.3%) dry cough (32.6%) while shortness breath was reported (75.6%) ICU admissions. Reported complications requiring admission included Sepsis...

10.1371/journal.pone.0242768 article EN cc-by PLoS ONE 2020-11-20

Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed concordance effects of immunosuppression their IBD patients.We searched MEDLINE, Embase Cochrane databases (2011-2018) studies...

10.5217/ir.2019.00116 article EN cc-by-nc Intestinal Research 2020-03-18

Nucleotide-binding oligomerization domain-containing two (NOD2/CARD15) gene polymorphisms are implicated in the pathogenesis of Crohn's disease (CD).To describe allelic frequency NOD2/CARD15 variants among Kuwaiti patients with CD and investigate potential genotype/phenotype associations.Adult citizens an established diagnosis healthy controls were enrolled from October 2018 to May 2020. Three common (R702W, G908R, L1007fs) P268S IVS8+158 screened by polymerase chain reaction/restriction...

10.4103/sjg.sjg_613_20 article EN cc-by-nc-sa Saudi Journal of Gastroenterology 2021-07-01

regression was used to find the best fitting model.ROC curves were most sensitive cut-off value.Results: Ninety-eight CD patients (41.8% male, mean±SD age 44.7 ± 14.2 years, 55.1% active disease) and 80 UC (58.8% 52.2 15.3 63.8% included.The multivariable logistic model for with a sensitivity of 90.4% (specificity 40.9%) included questions on blood loss, number stools, urgency, fatigue IBD symptoms in general.The 88.3% 65.5%) contained items abdominal pain general. Conclusions:We developed...

10.1093/ecco-jcc/jju027.352 article EN Journal of Crohn s and Colitis 2015-02-01

Abstract Disclosure: P. Chalasani: None. M. Asfaw: Mansour: Hammoud: T. Altaweel: H. Ilyas: L. Lawrence: Introduction: Hypopituitarism refers to the diminished or complete absence of anterior pituitary function, which may arise from acquired congenital factors. The symptoms depend on patient’s age and hormones affected. We report a case where hypoglycemia led new diagnosis panhypopituitarism in an adult patient. Clinical Case:A 53-year-old female with past medical history hypertension was...

10.1210/jendso/bvae163.1232 article EN cc-by-nc-nd Journal of the Endocrine Society 2024-10-01

10.1016/j.gie.2016.01.061 article EN Gastrointestinal Endoscopy 2016-02-04

Benign lymphoid polyps are uncommon lesions of the small bowel and colon to a lesser degree that mostly found in children. There only few reported cases adults which were predominantly polypoid described as lymphonodular hyperplasia. We present case large benign polyp transverse 64-year-old lady who was referred our care for history alteration her habit anemia. Colonoscopy showed 3 cm (Paris 1p) friable excised retrieved. Histopathology examination confirmed its nature supported by...

10.1155/2018/5758689 article EN cc-by Case Reports in Gastrointestinal Medicine 2018-10-28

Introduction: The long-term efficacy and safety of the anti tumor necrosis factor (TNF) agents infliximab (IFX) adalimumab (ADA) has been well established in treatment Crohn's disease (CD). However, direct head to studies comparing two over long periods time are sparse. aim our study was compare IFX ADA CD at McGill University Health Centre (MUHC). Methods: This is a single center retrospective based MUHC. We included adult patients with that were anti-TNF naive treated either or ADA....

10.14309/00000434-201610001-00729 article EN The American Journal of Gastroenterology 2016-10-01

with TAC (initially 0.05 mg/kg twice a day orally, then adjusted aiming for serum trough levels of 10-20 ng/mL).Thiopurine maintenance therapy was adapted to patients who responded TAC, and ceased after 3 months.Primary endpoint comparison cumulative probability continuing each colectomy-free rate during follow-up.Secondary endpoints were clinical remission or response at week 10 based on partial Mayo score serious-adverse-event rates follow-up.Results: Anti-TNF-antibodies have higher...

10.1093/ecco-jcc/jjw019.649 article EN Journal of Crohn s and Colitis 2016-03-01
Coming Soon ...